La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Innate Pharma Gestione

Gestione criteri di controllo 4/4

Innate Pharma's Il CEO è Herve Brailly, nominato in Jan1999, ha un mandato di 25.58 anni. possiede direttamente 0.91% delle azioni della società, per un valore di € 1.53M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.5 anni e 5.8 anni.

Informazioni chiave

Herve Brailly

Amministratore delegato

€100.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	25.6yrs
Proprietà del CEO	0.9%
Durata media del management	4.5yrs
Durata media del Consiglio di amministrazione	5.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price

May 21

Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Mar 24

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Dec 21

Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher

Sep 30

Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates

Sep 16

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Jun 09

News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts

Mar 30

Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic

Dec 18

Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?

Sep 27

Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year

Aug 04

Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

May 12

Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Apr 13

Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook

Mar 26

Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?

Nov 11

Revenue Downgrade: Here's What Analysts Forecast For Innate Pharma S.A. (EPA:IPH)

May 13

Is Innate Pharma (EPA:IPH) Using Debt Sensibly?

May 04

A Look At Innate Pharma's (EPA:IPH) Share Price Returns

Feb 26

AMMINISTRATORE DELEGATO

Herve Brailly (63 yo)

25.6yrs

Mandato

€100,000

Compensazione

Dr. Herve Brailly, Ph.D. Co-Founded Innate Pharma S.A in 1999 and served as its Chairman of Supervisory Board since December 31, 2016 until January 1, 2024 and serves as its Interim CEO and Chairman of the...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Herve Brailly	Co-Founder	25.6yrs	€100.00k	0.91% € 1.5m
Yannis Morel	Executive VP	9.3yrs	€599.92k	0.24% € 404.9k
François Romagné	Founder	no data	Nessun dato	Nessun dato
Eric Vivier	Founder	6.6yrs	Nessun dato	0.26% € 438.3k
Marc Bonneville	Founder	no data	Nessun dato	Nessun dato
Jean Fournié	Founder	no data	Nessun dato	Nessun dato
Alessandro Moretta	Founder	no data	Nessun dato	Nessun dato
Frederic Lombard	Senior VP & CFO	3.3yrs	Nessun dato	0.014% € 23.7k
Sonia Quaratino	Executive VP	less than a year	Nessun dato	Nessun dato
Arvind Sood	Executive VP	less than a year	Nessun dato	Nessun dato
Henry Wheeler	Vice President of Investor Relations & Communication	1.6yrs	Nessun dato	0.0039% € 6.6k
Odile Belzunce	Vice President of Compliance & Operations	5.6yrs	Nessun dato	0.077% € 129.8k

4.5yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di IPH è considerato esperto (durata media dell'incarico 4.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Mario Sznol	Strategic Advisory Board Member	5.8yrs	Nessun dato	Nessun dato
Olivier Martinez	Member of Supervisory Board	no data	Nessun dato	Nessun dato
Ruslan Medzhitov	Strategic Advisory Board Member	5.8yrs	Nessun dato	Nessun dato
Gilles Brisson	Independent Member of Supervisory Board	17.2yrs	€29.00k	0.090% € 152.3k
Jean-Yves Blay	Independent Member of Supervisory Board	6.7yrs	€29.00k	0.000060% € 101.3
Irina Staatz-Granzer	Independent Chairwoman of Supervisory Board	15.2yrs	€42.00k	0.031% € 52.3k
Pascale Boissel	Independent Vice Chairperson of the Supervisory Board	4.3yrs	€60.00k	0.0012% € 2.1k
Miriam Merad	Chairman of Strategic Advisory Board	5.8yrs	Nessun dato	Nessun dato
Veronique Chabernaud	Independent Member of Supervisory Board	9.3yrs	€48.00k	0.00082% € 1.4k
Sebastian Amigorena	Strategic Advisory Board Member	5.8yrs	Nessun dato	Nessun dato
Aurelien Marabelle	Strategic Advisory Board Member	5.8yrs	Nessun dato	Nessun dato
Tanguy Seiwert	Strategic Advisory Board Member	5.8yrs	Nessun dato	Nessun dato

5.8yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IPH sono considerati esperti (durata media dell'incarico 5.8 anni).

Innate Pharma Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Supervisory Board Changes

Recent updates

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

New minor risk - Profitability

No longer forecast to breakeven

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Consensus estimates of losses per share improve by 14%

Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Consensus EPS estimates increase from loss to €0.21 profit

Forecast to breakeven in 2026

Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

New minor risk - Share price stability

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher

Consensus revenue estimates increase by 13%

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Consensus revenue estimates fall by 18%

First half 2023 earnings released: EPS: €0.021 (vs €0.08 in 1H 2022)

Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Consensus revenue estimates decrease by 40%, EPS upgraded

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Price target increased by 8.3% to €6.37

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts

No longer forecast to breakeven

Consensus revenue estimates increase by 340%

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic

Consensus revenue estimates increase by 11%

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Price target decreased to €6.18

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Consensus estimates of losses per share improve by 41%

First half 2022 earnings: EPS and revenues exceed analyst expectations

Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year

Consensus revenue estimates fall by 11%

Price target decreased to €7.48

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Consensus EPS estimates have been downgraded.

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Consensus forecasts updated

Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Consensus forecasts updated

Consensus forecasts updated

Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?

Price target increased to €7.77

First half 2021 earnings released: €0.30 loss per share (vs €0.13 loss in 1H 2020)

Innate Pharma SA Announces Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia

Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides

Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting